AMD3100 affects autograft lymphocyte collection and progression-free survival after autologous stem cell transplantion in non-Hodgkin lymphoma

Shernan G. Holtan, Luis F. Porrata, Ivana Micallef, Douglas J. Padley, David J. Inwards, Stephen Maxted Ansell, Patrick Bruce Johnston, Dennis A. Gastineau, Svetomir Nenad Markovic

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

Purpose: Autograft absolute lymphocyte count (A-ALC) affects survival after autologous stem cell transplantation (ASCT) in non-Hodgkin lymphoma (NHL). AMD3100, a CXCR4 antagonist, mobilizes CD34+ stem cells in patients with NHL undergoing ASCT. We sought to study the impact of AMD3100 on A-ALC collection in patients with NHL undergoing ASCT. Patients and Methods: The primary endpoint of the study was to assess the association between AMD3100 and A-ALC collection. We compared 7 consecutive patients with NHL mobilized with AMD3100 and granulocyte colony-stimulating factor with 29 control patients with NHL mobilized with granulocyte colony-stimulating factor alone. Results: Higher median A-ALCs were observed in the AMD3100 group compared with the control group (4.16 × 109 lymphocytes/kg vs. 0.288 × 109 lymphocytes/kg; P < 0.0001). With a median follow-up of 20 months (range, 4-24 months), no relapses were reported in the AMD3100 group compared with 15 of 29 in the control group (P < 0.02). Conclusion: Our data suggest that AMD3100 affects A-ALC and clinical outcome in patients with NHL undergoing ASCT.

Original languageEnglish (US)
Pages (from-to)315-318
Number of pages4
JournalClinical Lymphoma and Myeloma
Volume7
Issue number4
DOIs
StatePublished - Jan 2007

Fingerprint

Autografts
Non-Hodgkin's Lymphoma
Disease-Free Survival
Stem Cells
Lymphocytes
Lymphocyte Count
Stem Cell Transplantation
Granulocyte Colony-Stimulating Factor
Control Groups
JM 3100
Recurrence
Survival

Keywords

  • Autograft absolute lymphocyte count
  • Endpoint
  • Granulocyte colony-stimulating factor

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Hematology

Cite this

AMD3100 affects autograft lymphocyte collection and progression-free survival after autologous stem cell transplantion in non-Hodgkin lymphoma. / Holtan, Shernan G.; Porrata, Luis F.; Micallef, Ivana; Padley, Douglas J.; Inwards, David J.; Ansell, Stephen Maxted; Johnston, Patrick Bruce; Gastineau, Dennis A.; Markovic, Svetomir Nenad.

In: Clinical Lymphoma and Myeloma, Vol. 7, No. 4, 01.2007, p. 315-318.

Research output: Contribution to journalArticle

@article{fd4a0bcd4b8a4dfd8972233e3a8a1802,
title = "AMD3100 affects autograft lymphocyte collection and progression-free survival after autologous stem cell transplantion in non-Hodgkin lymphoma",
abstract = "Purpose: Autograft absolute lymphocyte count (A-ALC) affects survival after autologous stem cell transplantation (ASCT) in non-Hodgkin lymphoma (NHL). AMD3100, a CXCR4 antagonist, mobilizes CD34+ stem cells in patients with NHL undergoing ASCT. We sought to study the impact of AMD3100 on A-ALC collection in patients with NHL undergoing ASCT. Patients and Methods: The primary endpoint of the study was to assess the association between AMD3100 and A-ALC collection. We compared 7 consecutive patients with NHL mobilized with AMD3100 and granulocyte colony-stimulating factor with 29 control patients with NHL mobilized with granulocyte colony-stimulating factor alone. Results: Higher median A-ALCs were observed in the AMD3100 group compared with the control group (4.16 × 109 lymphocytes/kg vs. 0.288 × 109 lymphocytes/kg; P < 0.0001). With a median follow-up of 20 months (range, 4-24 months), no relapses were reported in the AMD3100 group compared with 15 of 29 in the control group (P < 0.02). Conclusion: Our data suggest that AMD3100 affects A-ALC and clinical outcome in patients with NHL undergoing ASCT.",
keywords = "Autograft absolute lymphocyte count, Endpoint, Granulocyte colony-stimulating factor",
author = "Holtan, {Shernan G.} and Porrata, {Luis F.} and Ivana Micallef and Padley, {Douglas J.} and Inwards, {David J.} and Ansell, {Stephen Maxted} and Johnston, {Patrick Bruce} and Gastineau, {Dennis A.} and Markovic, {Svetomir Nenad}",
year = "2007",
month = "1",
doi = "10.3816/CLM.2007.n.009",
language = "English (US)",
volume = "7",
pages = "315--318",
journal = "Clinical Lymphoma, Myeloma and Leukemia",
issn = "2152-2669",
publisher = "Cancer Media Group",
number = "4",

}

TY - JOUR

T1 - AMD3100 affects autograft lymphocyte collection and progression-free survival after autologous stem cell transplantion in non-Hodgkin lymphoma

AU - Holtan, Shernan G.

AU - Porrata, Luis F.

AU - Micallef, Ivana

AU - Padley, Douglas J.

AU - Inwards, David J.

AU - Ansell, Stephen Maxted

AU - Johnston, Patrick Bruce

AU - Gastineau, Dennis A.

AU - Markovic, Svetomir Nenad

PY - 2007/1

Y1 - 2007/1

N2 - Purpose: Autograft absolute lymphocyte count (A-ALC) affects survival after autologous stem cell transplantation (ASCT) in non-Hodgkin lymphoma (NHL). AMD3100, a CXCR4 antagonist, mobilizes CD34+ stem cells in patients with NHL undergoing ASCT. We sought to study the impact of AMD3100 on A-ALC collection in patients with NHL undergoing ASCT. Patients and Methods: The primary endpoint of the study was to assess the association between AMD3100 and A-ALC collection. We compared 7 consecutive patients with NHL mobilized with AMD3100 and granulocyte colony-stimulating factor with 29 control patients with NHL mobilized with granulocyte colony-stimulating factor alone. Results: Higher median A-ALCs were observed in the AMD3100 group compared with the control group (4.16 × 109 lymphocytes/kg vs. 0.288 × 109 lymphocytes/kg; P < 0.0001). With a median follow-up of 20 months (range, 4-24 months), no relapses were reported in the AMD3100 group compared with 15 of 29 in the control group (P < 0.02). Conclusion: Our data suggest that AMD3100 affects A-ALC and clinical outcome in patients with NHL undergoing ASCT.

AB - Purpose: Autograft absolute lymphocyte count (A-ALC) affects survival after autologous stem cell transplantation (ASCT) in non-Hodgkin lymphoma (NHL). AMD3100, a CXCR4 antagonist, mobilizes CD34+ stem cells in patients with NHL undergoing ASCT. We sought to study the impact of AMD3100 on A-ALC collection in patients with NHL undergoing ASCT. Patients and Methods: The primary endpoint of the study was to assess the association between AMD3100 and A-ALC collection. We compared 7 consecutive patients with NHL mobilized with AMD3100 and granulocyte colony-stimulating factor with 29 control patients with NHL mobilized with granulocyte colony-stimulating factor alone. Results: Higher median A-ALCs were observed in the AMD3100 group compared with the control group (4.16 × 109 lymphocytes/kg vs. 0.288 × 109 lymphocytes/kg; P < 0.0001). With a median follow-up of 20 months (range, 4-24 months), no relapses were reported in the AMD3100 group compared with 15 of 29 in the control group (P < 0.02). Conclusion: Our data suggest that AMD3100 affects A-ALC and clinical outcome in patients with NHL undergoing ASCT.

KW - Autograft absolute lymphocyte count

KW - Endpoint

KW - Granulocyte colony-stimulating factor

UR - http://www.scopus.com/inward/record.url?scp=33947184359&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33947184359&partnerID=8YFLogxK

U2 - 10.3816/CLM.2007.n.009

DO - 10.3816/CLM.2007.n.009

M3 - Article

C2 - 17324341

AN - SCOPUS:33947184359

VL - 7

SP - 315

EP - 318

JO - Clinical Lymphoma, Myeloma and Leukemia

JF - Clinical Lymphoma, Myeloma and Leukemia

SN - 2152-2669

IS - 4

ER -